Cleerly ISCHEMIA vs EchoGo Pro

EchoGo Pro emphasizes a cloud-based SaaS model requiring no software installation or extensive training, and offers seamless integration with existing clinical workflows (DICOM, HL7) and compatibility with any PACS. Cleerly ISCHEMIA, while web-based, mentions data transfer via a Cleerly Proxy, which might imply a slightly more involved setup compared to EchoGo Pro's pure SaaS and vendor-neutral approach.

Cleerly ISCHEMIA provides a more granular and comprehensive analysis from CCTA scans, including non-invasive fractional flow reserve (FFR) estimation, vessel-level ischemia likelihood, and detailed coronary plaque characterization (volume, type, location, stenosis severity). This offers a deeper level of insight for personalized diagnosis and treatment planning compared to EchoGo Pro's automated stress echocardiography analysis. Cleerly ISCHEMIA has also demonstrated prognostic utility for future MACE events in clinical trials.

While both tools require contacting the vendor for pricing, Cleerly ISCHEMIA explicitly states it is billable under Category I CPT Code 75580 for non-invasive FFR estimation and CPT Code 75577 for plaque analysis, with a global reimbursement rate of $1,026 for the latter effective January 1, 2026. This provides a clearer and more established reimbursement pathway for providers, indicating a stronger value proposition in terms of financial sustainability. EchoGo Pro mentions reimbursement codes for *related* products, but not directly for EchoGo Pro itself.

Both tools are FDA-cleared, HIPAA compliant, and offer Business Associate Agreements (BAAs), which are foundational for enterprise readiness. However, EchoGo Pro's explicit mention of being a 'vendor-neutral system, compatible with any PACS' and offering 'seamless integration with existing clinical workflows (DICOM, HL7)' suggests a broader and potentially easier integration into diverse hospital IT environments. Cleerly ISCHEMIA's integration with PowerScribe via API and use of a Cleerly Proxy are more specific and might require more tailored IT efforts.

Cleerly ISCHEMIA's ability to non-invasively estimate fractional flow reserve (FFR) and provide detailed characterization of coronary plaque (volume, type, location) from CCTA scans represents a significant innovation in non-invasive cardiac diagnostics. This moves beyond traditional anatomical assessment to include functional significance and plaque vulnerability, offering a more comprehensive understanding of coronary artery disease. While EchoGo Pro's automated echocardiography is innovative, Cleerly's specific insights from CCTA appear to push the boundaries further.

Both companies demonstrate a commitment to support and documentation. Cleerly offers a dedicated support page with contact forms, email support, specified operating hours, and resources like publications and FAQs. Ultromics also provides customer support channels, contact forms, and a range of resources including webinars, articles, and a 'Clinical Research Dossier'. Without more specific comparative data on the quality or responsiveness of support, it is difficult to distinguish a clear winner.